[go: up one dir, main page]

DE60005501D1 - 4'-c-ethynyl-pyrimidine nukleoside - Google Patents

4'-c-ethynyl-pyrimidine nukleoside

Info

Publication number
DE60005501D1
DE60005501D1 DE60005501T DE60005501T DE60005501D1 DE 60005501 D1 DE60005501 D1 DE 60005501D1 DE 60005501 T DE60005501 T DE 60005501T DE 60005501 T DE60005501 T DE 60005501T DE 60005501 D1 DE60005501 D1 DE 60005501D1
Authority
DE
Germany
Prior art keywords
ethynyl
pyrimidine nucleosides
hydrogen atom
pyrimidine
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60005501T
Other languages
English (en)
Other versions
DE60005501T2 (de
Inventor
Hiroshi Ohrui
Shiro Shigeta
Eiichi Kodama
Haruhiko Machida
Satoru Kohgo
Hiroaki Mitsuya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamasa Corp
Original Assignee
Yamasa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamasa Corp filed Critical Yamasa Corp
Publication of DE60005501D1 publication Critical patent/DE60005501D1/de
Application granted granted Critical
Publication of DE60005501T2 publication Critical patent/DE60005501T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE60005501T 1999-05-12 2000-05-11 4'-c-ethynyl-pyrimidine nukleoside Expired - Lifetime DE60005501T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP13153999 1999-05-12
JP13153999 1999-05-12
JP17492099 1999-06-22
JP17492099 1999-06-22
JP31824699 1999-11-09
JP31824699 1999-11-09
JP2000081117 2000-03-23
JP2000081117 2000-03-23
PCT/JP2000/003024 WO2000069876A1 (en) 1999-05-12 2000-05-11 4'-c-ethynyl pyrimidine nucleosides

Publications (2)

Publication Number Publication Date
DE60005501D1 true DE60005501D1 (de) 2003-10-30
DE60005501T2 DE60005501T2 (de) 2004-06-24

Family

ID=27471622

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60005501T Expired - Lifetime DE60005501T2 (de) 1999-05-12 2000-05-11 4'-c-ethynyl-pyrimidine nukleoside
DE60005502T Expired - Lifetime DE60005502T2 (de) 1999-05-12 2000-05-11 4'-c-ethynyl-purin-nukleoside

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60005502T Expired - Lifetime DE60005502T2 (de) 1999-05-12 2000-05-11 4'-c-ethynyl-purin-nukleoside

Country Status (10)

Country Link
US (3) US6291670B1 (de)
EP (2) EP1177202B1 (de)
AT (2) ATE250622T1 (de)
AU (2) AU4431300A (de)
BR (1) BR0011521B8 (de)
CA (2) CA2308677C (de)
DE (2) DE60005501T2 (de)
ES (1) ES2207504T3 (de)
MX (1) MXPA01011517A (de)
WO (2) WO2000069876A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE250622T1 (de) * 1999-05-12 2003-10-15 Yamasa Corp 4'-c-ethynyl-pyrimidine nukleoside
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US20040006002A1 (en) * 2001-09-28 2004-01-08 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
AU2003211483A1 (en) * 2002-02-15 2003-09-04 Yamasa Corporation 4'-c-cyano-2'-deoxypurine nucleosides
EP1653976A4 (de) 2003-02-19 2009-07-29 Univ Yale Anti-virale nucleosid-analoga und verfahren zur behandlung von virusinfektionen, insbesondere hiv-infektionen
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
DE602005015466D1 (de) 2004-08-23 2009-08-27 Hoffmann La Roche Antivirale 4'-azidonucleoside
BRPI0616738A2 (pt) * 2005-09-26 2011-06-28 Pharmasset Inc 4'-nucleosìdeos modificados como agentes antivirais
SI2084175T1 (sl) 2006-10-10 2011-05-31 Medivir Ab Hcv nukleozidni inhibitor
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
AU2012358803C1 (en) * 2011-12-22 2019-12-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9862743B2 (en) 2013-10-11 2018-01-09 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
AU2016328303B2 (en) 2015-09-23 2019-05-02 Merck Sharp & Dohme (Uk) Limited 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
WO2018092728A1 (ja) 2016-11-16 2018-05-24 国立研究開発法人国立国際医療研究センター 抗ウイルス活性等の生理活性を有するヌクレオシド誘導体
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
WO2019133712A1 (en) * 2017-12-27 2019-07-04 Schinazi Raymond F Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
BR112021000202B1 (pt) * 2018-07-09 2023-03-28 Merck Sharp & Dohme Llc Métodos para síntese enzimática de nucleosídeo 4'-etinila 2-desóxi e compostos
JP2021536444A (ja) * 2018-08-30 2021-12-27 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Ｈｉｖ療法に有用な化合物
KR20210105931A (ko) 2018-12-20 2021-08-27 머크 샤프 앤드 돔 코포레이션 Nrtti 화합물의 신규 결정질 형태
AU2020211600A1 (en) 2019-01-25 2021-07-22 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
MA55200A (fr) 2019-03-06 2022-01-12 Glaxosmithkline Ip No 2 Ltd Composés utiles dans la thérapie du vih
EP4021916A1 (de) * 2019-08-28 2022-07-06 GlaxoSmithKline Intellectual Property (No. 2) Limited 4'-ethynyl-2'-deoxyadenosinderivate und ihre verwendung in der hiv-therapie
EP4121437A1 (de) 2020-03-20 2023-01-25 Gilead Sciences, Inc. Prodrugs von 4'-c-substituierten-2-halo-2'-deoxyadenosinnukleosiden und verfahren zur herstellung und verwendung davon
PE20250684A1 (es) 2022-03-15 2025-03-04 Rome Therapeutics Inc Compuestos y metodos para el tratamiento de enfermedades

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE250622T1 (de) * 1999-05-12 2003-10-15 Yamasa Corp 4'-c-ethynyl-pyrimidine nukleoside

Also Published As

Publication number Publication date
MXPA01011517A (es) 2003-08-20
BR0011521A (pt) 2002-03-26
US6403568B1 (en) 2002-06-11
EP1177202A1 (de) 2002-02-06
EP1177201A1 (de) 2002-02-06
EP1177201B1 (de) 2003-09-24
DE60005502D1 (de) 2003-10-30
WO2000069876A1 (en) 2000-11-23
ATE250622T1 (de) 2003-10-15
CA2308677C (en) 2007-09-18
ATE250623T1 (de) 2003-10-15
US6333315B1 (en) 2001-12-25
BR0011521B8 (pt) 2021-05-25
AU4431200A (en) 2000-12-05
WO2000069877A1 (en) 2000-11-23
EP1177202B1 (de) 2003-09-24
DE60005501T2 (de) 2004-06-24
CA2308677A1 (en) 2000-11-12
ES2207504T3 (es) 2004-06-01
CA2308192A1 (en) 2000-11-12
CA2308192C (en) 2007-09-18
US20020022722A1 (en) 2002-02-21
US6291670B1 (en) 2001-09-18
DE60005502T2 (de) 2004-06-24
BR0011521B1 (pt) 2013-12-24
AU4431300A (en) 2000-12-05

Similar Documents

Publication Publication Date Title
DE60005502D1 (de) 4'-c-ethynyl-purin-nukleoside
IL124537A0 (en) Naphthyl-substituted benzimidazole derivatives and pharmaceutical compositions containing the same
EP1334719A3 (de) Pentafluorobenzensulfonamide und Analoge
AU4264396A (en) Cosmetic or pharmaceutical compositions containing mangiferin or derivatives thereof
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
TR200103395T2 (tr) 13-metil eritromisin türevleri.
NO996108L (no) 9-oksinerytromycinderivater
GEP20084284B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
CA2336412A1 (en) Medicament for treatment of diabetes
NO20020282D0 (no) Nytt difenylpiperidinderivat
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
MX9805023A (es) Derivados de 1-metilcarbapenem.
ZA9510908B (en) Pharmaceutical compounds
DE69911785D1 (de) Triazolo[4,5-d]pyrimidin-verbindungen
ATE285771T1 (de) Diaminotrifluoromethylpyrimidinderivate enthaltende antikrebs-zusammensetzung
DE69007356D1 (de) Zyklisches Tetrapeptid und Verfahren zu dessen Herstellung.
IL147307A0 (en) Indolocarbazole alkaloid derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
WO2000024389A3 (en) Benzoquinoline derivatives useful as antibacterial agents
EA200001157A2 (ru) Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции
FR2823749B1 (fr) Phenyl- et pyridyl-piperidines, procede pour leur preparation et compositions pharmaceutiques les contenant
TW360630B (en) A secoaporphine compounds on arrhythmia
MX9604072A (es) Derivados de oxazolidinona y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition